

Technology Advisory Committee A Interests Register
Baricitinib for treating severe alopecia areata [ID3979]
Publication Date: 25/10/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dominic Pivonka	Committee Member	Indirect Financial interest	Dominic declared that his employer (AbbVie) has a medicine which is a competitor to baricitinib in other therapy areas (rheumatoid arthritis and atopic dermatitis)	N/A	27/01/2023	N/A	It was agreed that his declaration would prevent Dominic Pivonka, from providing expert advice.
Lynn Wilks	Patient Expert	Non direct financial interest	Lynn's organisation Alopecia UK has cooperate sponsorships/ memberships from Eli lily and ConcertPharma. As	N/A	10/11/2022 07/02/2023	N/A	It was agreed that her declaration would not prevent Lynn Wilks from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			well as winning a research grant from Pfizer.				
Sue Schilling	Patient Expert	Non direct financial interest	Sue's organisation Alopecia UK has cooperate sponsorships/ memberships from Eli lily and concert Pharma. Aswell as winning a research grant from Pfizer. It was agreed that his/her declaration would not prevent Lynn Wilks from providing expert advice to the committee.	N/A	09/06/22 07/2/23	N/A	It was agreed that her declaration would not prevent Sue Schilling from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Abby Macbeth	Clinical Expert	Direct professional Interest	Abby declared that because she works as the NIHR regional researcher and is part of the guideline group for BAD for alopecia areata. She has also co-authored epidemiology papers with a team from Pfizer but no payment was received. And has done charitable work for the UK dermatology clinical trials network and alopecia UK.	N/A	28/06/22 07/2/23	N/A	It was agreed that his declaration would not prevent Abby Macbeth, from providing expert advice.
Ben Farrar	EAG	Direct professional interest	Ben declared he was employed by a Costello medical who are a consultancy involved in the	N/A	06/02/2023	N/A	It was agreed that his declaration would not prevent Ben Farrar from providing expert

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			submission of this topic between September 2020 – December 2020 and November 2021 – May 2022 did not work on Baricitinib or other comparators.				advice to the committee.
Dr Steve Edwards	Committee Member	Non-financial professional	He is a member of the EAG that assessed Baricitinib for treating severe alopecia areata [ID3979]		20/01/2023		It was agreed that his declaration would prevent Dr Steve Edwards from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Matthew Harries	Clinical Expert	Direct financial interest	he has conducted consultancy work with Pfizer and Eli Lilly discussing treatment practices and outcome measures for AA in UK. He also declared an indirect interest as he is a local PI RCT Soterios for a topical treatment on AA. Prior to the meeting, Dr Matthew Harries also declared a direct financial interest as he is co-director of MJHarries Dermatology Ltd and declared direct non-financial interests as		29/06/2022 27/02/2022		

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			he is co-author on a meeting abstract exploring PRO correlation with disease severity in AA and co-author NEJM Editorial on the Phase 3 baricitinib trials in AA. He also declared indirect interests prior to the meeting as he is a committee member for Alopecia UK, British Skin Foundation and is also a committee lead for the BAD alopecia areata guidelines update Also Dr Matthew Harries also stated prior to the meeting				

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			that he is the co-lead for the NIHR Manchester BRC Inflammatory hair diseases programme.				